2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.057 Subhadeep Das NACLC23 Abstract

PP01.057 Subhadeep Das NACLC23 Abstract

Pdf Summary

A study conducted at Purdue University aimed to understand the molecular mechanism of Supinoxin, a compound with anti-cancer activity, on small cell lung cancer (SCLC) therapy. The researchers focused on DDX5, an RNA helicase that is overexpressed in SCLC. SCLC is a highly lethal cancer with limited treatment options. <br /><br />To assess the impact of Supinoxin on SCLC, the researchers conducted experiments using H69AR cell lines and immunocompromised mice with xenograft tumors. They found that Supinoxin inhibited the proliferation of H69AR cells and prevented colony formation in soft agar. In vivo experiments showed that Supinoxin reduced the growth of xenograft tumors in mice.<br /><br />The researchers also evaluated the expression levels of c-Myc, DDX5, and β-Catenin upon Supinoxin treatment. They used western blotting and immunofluorescence microscopy to assess the localization of β-Catenin and phosphor-DDX5. Surprisingly, the current model of Supinoxin activity did not hold true. There was no decrease in β-Catenin levels or relocalization upon Supinoxin treatment, and the expression levels of β-Catenin target genes were not reduced.<br /><br />Further analysis using differential gene expression (RNA-seq) identified potential pathways through which Supinoxin may act on SCLC. However, the precise molecular mechanisms of Supinoxin's action on SCLC remain unclear.<br /><br />In conclusion, the study showed that Supinoxin can impede the proliferation of SCLC cells, but the exact molecular mechanisms underlying its action need further investigation. Future studies will focus on elucidating the molecular mechanism through which Supinoxin operates on SCLC.

Keywords

Supinoxin

SCLC therapy

DDX5

H69AR cell lines

xenograft tumors

proliferation inhibition

c-Myc

β-Catenin

differential gene expression

molecular mechanisms